Efficacy Of Octreotide In Treatment Research Articles

Octreotide treatment of cancer chemoradiotherapy-induced diarrhoea: a meta-analysis of randomized controlled trials

Background: Patients receiving radiotherapy and chemotherapy have a high risk developing to an acute chemoradiotherapy-induced diarrhea (RID). The clinical efficacy of octreotide in controlling chemoradiotherapy-induced diarrhea remains controversial. We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of octreotide for treatment the chemoradiotherapy-induced diarrhoea. Methods: Relevant RCTs studies assessing the effect of octreotide on clinical outcomes compared with placebo were searched in Cochrane Library, PubMed, EMBASE and Web of Science (up to December 2018). Heterogeneity was assessed with I 2 , and publication bias was evaluated using sensitive analysis. Results: Eight trials, a total of 594 participants. We found octreotide was significantly effective compared with the control group (OR =3.17; 95% CI, 1.28–7.85; P Conclusions: Octreotide is superior to conventional therapy in the duration and effectiveness for chemoradiotherapy-induced diarrhea.

Octreotide treatment of cancer chemoradiotherapy-induced diarrhoea: a meta-analysis of randomized controlled trials.

BackgroundPatients receiving radiotherapy and chemotherapy have a high risk developing to an acute chemoradiotherapy-induced diarrhea (RID). The clinical efficacy of octreotide in controlling chemoradiotherapy-induced diarrhea remains controversial. We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of octreotide for treatment the chemoradiotherapy-induced diarrhoea.MethodsRelevant RCTs studies assessing the effect of octreotide on clinical outcomes compared with placebo were searched in Cochrane Library, PubMed, EMBASE and Web of Science (up to December 2018). Heterogeneity was assessed with I2, and publication bias was evaluated using sensitive analysis.ResultsEight trials, a total of 594 participants. We found octreotide was significantly effective compared with the control group (OR =3.17; 95% CI, 1.28–7.85; P<0.0001). The overall effect of octreotide was 62.5% (220/352), while that of the control group was 49.3% (168/341). We found octreotide group was effective compared with the control group in 24, 48, and 96 h (OR =16.02; 95% CI, 3.51–73.15; P=0.0003), (OR =4.70; 95% CI, 1.65–13.42; P=0.004) and (OR =14.49; 95% CI, 6.24–33.65; P<0.00001).ConclusionsOctreotide is superior to conventional therapy in the duration and effectiveness for chemoradiotherapy-induced diarrhea.

Efficacy of octreotide for treatment of cirrhosis with refractory ascites: A meta-analysis

Efficacy of octreotide for treatment of cirrhosis with refractory ascites: A meta-analysis

Use of octreotide as second-line treatment for concurrent chemoradiation induced diarrhea refractory to loperamide

3704 Background: To prospectively evaluate efficacy of octreotide in treatment of chemoradiation induced diarrhea refractory to conventional loperamide treatment. Methods: Our study consists of 38 intractable diarrhea patients resistant to loperamide, out of 56 colon/rectum adenocarcinoma patients (T3–4NXM0) treated at Department of Radiation Oncology, Inonu University, between September 2002 and April 2003. All patients were treated with conventional radiotherapy (50.4 Gy, 1.8 Gy/fraction) with high-energy photons and concurrent 500mg/m2/week i.v. bolus 5FU. Thirty-eight patients had Grade 3 or 4 gastrointestinal toxicity during chemoradiation, according to National Cancer Institute Common Toxicity Criteria (NCI-CTC). Diarrhea failed to improve after 48 hours of p.o. loperamide (4 mg tid) administration on outpatient basis. As 38 patients were assigned to receive octreotide (150 mg tid) subcutaneously for 5 consecutive days, 8 patients who required parenteral support due to severe cramping, incontinence, gross bloody diarrhea were not included in the trial. Complete resolution of diarrhea was considered therapeutic response, whereas partial or no improvement in diarrhea to octreotide application for 5 days was documented as therapeutic failure. Results: Diarrhea, recorded as NCI-CTC Grade 3 & 4, was largely experienced in the first two weekly cycles of 5FU administration concurrent with radiotherapy; 19 (50%) patients in the 1st, 11 (31.6%) in the 2nd, 4 (10.5%) in the 3rd, and 3 (7.9%) in the 4th cycles. Octreotide application resolved diarrhea completely in 33 patients out of 38 cases (86.8%) without any side effects (1st day, 5; 2nd day, 10; 3rd day, 15; 4th day, 2; and 5th day, 1 cases). Five octreotide irresponsive patients (13.2%) discontinued chemoradiation to receive further supportive treatment by parenteral support of fluids and electrolytes with alternative antidiarrheal treatments. Conclusions: Daily subcutaneous octreotide application for five days seems to be an effective, tolerable second-line treatment for concurrent chemoradiation induced diarrhea refractory to loperamide. No significant financial relationships to disclose.

Use of octreotide as second-line treatment for concurrent chemoradiation induced diarrhea refractory to loperamide

3704 Background: To prospectively evaluate efficacy of octreotide in treatment of chemoradiation induced diarrhea refractory to conventional loperamide treatment. Methods: Our study consists of 38 intractable diarrhea patients resistant to loperamide, out of 56 colon/rectum adenocarcinoma patients (T3–4NXM0) treated at Department of Radiation Oncology, Inonu University, between September 2002 and April 2003. All patients were treated with conventional radiotherapy (50.4 Gy, 1.8 Gy/fraction) with high-energy photons and concurrent 500mg/m2/week i.v. bolus 5FU. Thirty-eight patients had Grade 3 or 4 gastrointestinal toxicity during chemoradiation, according to National Cancer Institute Common Toxicity Criteria (NCI-CTC). Diarrhea failed to improve after 48 hours of p.o. loperamide (4 mg tid) administration on outpatient basis. As 38 patients were assigned to receive octreotide (150 mg tid) subcutaneously for 5 consecutive days, 8 patients who required parenteral support due to severe cramping, incontinence, gross bloody diarrhea were not included in the trial. Complete resolution of diarrhea was considered therapeutic response, whereas partial or no improvement in diarrhea to octreotide application for 5 days was documented as therapeutic failure. Results: Diarrhea, recorded as NCI-CTC Grade 3 & 4, was largely experienced in the first two weekly cycles of 5FU administration concurrent with radiotherapy; 19 (50%) patients in the 1st, 11 (31.6%) in the 2nd, 4 (10.5%) in the 3rd, and 3 (7.9%) in the 4th cycles. Octreotide application resolved diarrhea completely in 33 patients out of 38 cases (86.8%) without any side effects (1st day, 5; 2nd day, 10; 3rd day, 15; 4th day, 2; and 5th day, 1 cases). Five octreotide irresponsive patients (13.2%) discontinued chemoradiation to receive further supportive treatment by parenteral support of fluids and electrolytes with alternative antidiarrheal treatments. Conclusions: Daily subcutaneous octreotide application for five days seems to be an effective, tolerable second-line treatment for concurrent chemoradiation induced diarrhea refractory to loperamide. No significant financial relationships to disclose.

In vivo and in vitro efficacy of octreotide for treatment of enteric cryptosporidiosis.

Previous evidence suggested a role of enterotoxin in the pathophysiology of cryptosporidiosis. If so, antisecretory drugs should be effective in reducing diarrhea. We evaluated the in vivo and in vitro efficacy of octreotide, which possesses antisecretory effects, for cryptosporidial diarrhea. Two children with severe cryptosporidial diarrhea were treated with octreotide. The volume modifications and chemical composition of stools were determined. Fecal supernatant was added to Caco-2 cell monolayers mounted in Ussing chambers with or without serosal octreotide and electrical parameters were monitored. Octreotide was effective in reducing the stool volume and fecal Na+ concentration. Fecal supernatant induced an enterotoxin-like increase in transepithelial potential difference. Octreotide induced a dose-dependent decrease in basal potential difference, consistent with an absorptive effect. In cells pretreated with octreotide, fecal supernatant induced an increase in the potential difference, whose magnitude and duration were significantly reduced compared to untreated cells. These results provide in vivo and in vitro evidence for the secretory nature of cryptosporidial diarrhea and for the efficacy of octreotide through a direct interaction with the enterocyte.